BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Arthur Klausner to participate in the panel "Alternatives for Creating Value in a challenging time" at NASDAQ Healthcare Industry Forum in New York City
News | 12. 08. 2008
